RAPT Therapeutics(US:RAPT) Prnewswire·2026-01-20 19:34Core Viewpoint - Monteverde & Associates PC is investigating the proposed sale of RAPT Therapeutics, Inc. to GSK plc, where RAPT shareholders are expected to receive $58.00 in cash per share, raising questions about the fairness of the deal [1]. Group 1: Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is located in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Group 2: Transaction Details - The proposed transaction involves RAPT Therapeutics, Inc. selling to GSK plc, with shareholders set to receive $58.00 in cash for each share of RAPT common stock [1]. - The investigation aims to determine whether this transaction is fair for RAPT shareholders [1].